Dyslipidemia in women with polycystic ovary syndrome
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Dyslipidemia is a very common metabolic abnormality in women with polycystic ovary syndrome (PCOS). Insulin resistance is a key pathophysiology of PCOS, thus dyslipidemia in women with PCOS may be consistent with those found in an insulin resistant state. In recent meta-analysis, triglycerides and low-density lipoprotein (LDL) cholesterol levels were 26 mg/dL and 12 mg/dL higher, and high-density lipoprotein cholesterol concentration was 6 mg/dL lower in women with PCOS than those of controls. Alterations in LDL quality also have been reported in women with PCOS: women with PCOS have an increased proportion of atherogenic small dense LDL or decreased mean LDL particle size. However, in a recent Korean study, non-obese Korean women with PCOS had no significant quantitative or qualitative changes in LDL cholesterol profile. Lipoprotein (a) has been identified as an independent risk factor for coronary heart disease, and its elevation in PCOS patients has been consistently reported in diverse studies including non-obese Korean population. Some studies have investigated apolipoprotein (Apo) A-I and ApoC-I levels in women with PCOS and levels of ApoA-I, which has cardio-protective effects, were significantly lower in women with PCOS than those of controls. ApoC-I is known to increase the postprandial serum lipid level that is common in coronary artery disease patients, and one study reported that such an elevation may be the earliest variation of lipid abnormality in women with PCOS. In conclusion, women with PCOS should receive a complete lipid test, and lifestyle modification, including diet and exercise, is the first line therapy for all women with PCOS and is particularly important for those with dyslipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010 · cited 1×
“In addition to improvement of lipid profiles, PCOS women receiving statins showed a significant decrease of testosterone, free androgen index, C-reactive protein, and insulin resistance [42-44].”
BackgroundPrevalence and predictors of dyslipidemia in women with polycystic ovary syndrome
Legro, R. S., Kunselman, A. R., & Dunaif, A. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00948-2 · Cited by 622 · cited 3×
“Many studies have reported that LDL-C is increased in women with PCOS [3,21], which is usually not noted in insulin resistant states.”
BackgroundLipid Levels in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis
Wild, R. A., Rizzo, M., Clifton, S., & Carmina, E. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.12.027 · Cited by 477 · cited 2×
“[17] reported meta-analysis of lipid levels in world-wide cross-sectional studies in women with PCOS (mainly performed in European and American women).”
BackgroundDyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Brunzell, J. D., & Ayyobi, A. F. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.011 · Cited by 155 · cited 1×
“Insulin resistance is a key pathophysiology of PCOS, and dyslipidemia in women with PCOS may therefore be consistent with that found in the insulin resistant state: decreased levels of high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein (Apo) A-I, and increased levels of triglycerides (TG), ApoB and very l…”
BackgroundBanaszewska, B., Pawelczyk, L., Spaczynski, R. Z., Dziura, J., & Duleba, A. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1988 · Cited by 143
Berneis, K., Rizzo, M., Lazzaroni, V., Fruzzetti, F., & Carmina, E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1705 · Cited by 121 · cited 2×
“Women with PCOS have an increased proportion of atherogenic small dense LDL or decreased mean LDL particle size [14,25-31], and such alterations may be associated with increased cardiovascular risk.”
BackgroundLipoprotein(a): more interesting than ever after 50 years
Dubé, J. B., Boffa, M. B., Hegele, R. A., & Koschinsky, M. L. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835111d8 · Cited by 105
Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome
Berneis, K., Rizzo, M., Hersberger, M., Rini, G. B., Di Fede, G., Pepe, I., Spinas, G. A., & Carmina, E. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01897.x · Cited by 94
Cited by
Almenning, I., Rieber-Mohn, A., Lundgren, K. M., Shetelig Løvvik, T., Garnæs, K. K., & Moholdt, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138793 · Cited by 155
Abdalla, M. A., Shah, N., Deshmukh, H., Sahebkar, A., Östlundh, L., Al-Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221127142 · Cited by 33
Jethaliya, H., Gajjar, N., Patel, V., Deshpande, S., & Patel, R. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-00933-y · Cited by 17
Metadata
- Authors
- Kim, J. J., & Choi, Y. M.
- Venue
- Obstetrics & Gynecology Science
- Published
- 2013
- Volume
- 56
- Issue
- 3
- Pages
- 137
- ISSN
- 2287-8572 (ISSN-L)
- 2287-8580
- OpenAlex
- W2164271065
- Cited by
- 190
- References
- 10
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dyslipidemia in women with polycystic ovary syndrome. https://app.cochat.ai/papers/10.5468/ogs.2013.56.3.137
- The paper
- Kim, J. J., & Choi, Y. M. (2013). Dyslipidemia in women with polycystic ovary syndrome. Obstetrics & Gynecology Science. https://doi.org/10.5468/ogs.2013.56.3.137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.